Cyclana Bio secured £5 million in pre‑seed funding co‑led by NfX and Eka Ventures to advance a tissue‑based discovery platform aimed at women’s health. The Cambridge startup plans to use the proceeds to develop functional disease models and identify drug targets for endometriosis using menstrual fluid samples and extracellular matrix–focused lab models. Cyclana’s founders, Léa Wenger and Kevin Chalut, positioned the company as building drug discovery from tissue‑level biology rather than single‑cell assays. The round includes angel investors and VCs and will support early biomarker and target validation work for a disease that currently has limited therapeutic options.